JPH10316573A - 製薬投与単位体 - Google Patents

製薬投与単位体

Info

Publication number
JPH10316573A
JPH10316573A JP10112312A JP11231298A JPH10316573A JP H10316573 A JPH10316573 A JP H10316573A JP 10112312 A JP10112312 A JP 10112312A JP 11231298 A JP11231298 A JP 11231298A JP H10316573 A JPH10316573 A JP H10316573A
Authority
JP
Japan
Prior art keywords
dosage unit
starch
tibolone
carrier
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10112312A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10316573A5 (enExample
Inventor
De Pieter Haan
ピーター・デ・ハーン
Hurk Thedora Antonia Maria Lambregts-De
テオドラ・アントニア・マリア・ランブレツ−フアン・デ・ハルク
Adrianus Cornelis Petrus Rovers
アドリアヌス・コルネリス・ペトルス・ロフエルス
Jocominus Antonius M Zwinkels
ヨコミヌス・アントニウス・マリア・ズウインケルス
Ryoichi Morita
亮一 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of JPH10316573A publication Critical patent/JPH10316573A/ja
Publication of JPH10316573A5 publication Critical patent/JPH10316573A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP10112312A 1997-04-22 1998-04-22 製薬投与単位体 Pending JPH10316573A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL97201180.3 1997-04-22
EP97201180 1997-04-22

Publications (2)

Publication Number Publication Date
JPH10316573A true JPH10316573A (ja) 1998-12-02
JPH10316573A5 JPH10316573A5 (enExample) 2005-09-22

Family

ID=8228228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10112312A Pending JPH10316573A (ja) 1997-04-22 1998-04-22 製薬投与単位体

Country Status (25)

Country Link
US (6) US6399594B2 (enExample)
EP (1) EP0975348B1 (enExample)
JP (1) JPH10316573A (enExample)
KR (1) KR100580855B1 (enExample)
CN (2) CN1146424C (enExample)
AR (1) AR012480A1 (enExample)
AT (1) ATE281836T1 (enExample)
AU (1) AU742037B2 (enExample)
BR (1) BR9809268A (enExample)
CA (1) CA2288070A1 (enExample)
DE (1) DE69827484T2 (enExample)
DK (1) DK0975348T3 (enExample)
ES (1) ES2232949T3 (enExample)
HU (1) HUP0001780A3 (enExample)
ID (1) ID22763A (enExample)
IL (1) IL123984A (enExample)
NO (1) NO995127D0 (enExample)
NZ (1) NZ338028A (enExample)
PL (1) PL190227B1 (enExample)
PT (1) PT975348E (enExample)
RU (1) RU2207133C2 (enExample)
TR (1) TR199902530T2 (enExample)
TW (1) TW570798B (enExample)
WO (1) WO1998047517A1 (enExample)
ZA (1) ZA983169B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100432093C (zh) * 1998-10-16 2008-11-12 欧加农股份有限公司 包含（7α,17α)-17-羟基-7-甲基-19-去甲-17-孕-5（10）-烯-20-炔-3-酮的高纯度组合物

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1163901B1 (en) * 1999-02-26 2008-09-10 Shionogi & Co., Ltd. Chewable soft capsules having improved administration properties and process for producing the same
US20040229854A1 (en) * 2000-11-28 2004-11-18 Pieter Haan De Immediate release dosage form for HRT
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
KR100979877B1 (ko) * 2001-09-28 2010-09-02 뉴트라슈틱스 인코포레이티드 생물학적 성분의 전달 시스템
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
CN1324041C (zh) * 2003-04-01 2007-07-04 上海迪赛诺医药科技开发有限公司 替勃龙晶型i的制备方法
KR20060006949A (ko) * 2003-04-29 2006-01-20 아크조 노벨 엔.브이. 반용매 고화 방법
ES2243919T3 (es) * 2003-05-23 2005-12-01 Akzo Nobel N.V. Formulacion solida farmaceutica que contiene tibolona.
WO2005105278A2 (en) * 2004-05-05 2005-11-10 Akzo Nobel N.V. Antisolvent emulsion solidification process
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
WO2005120517A1 (en) * 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
CN102085193B (zh) * 2009-12-08 2013-11-06 北京以岭生物工程技术有限公司 一种替勃龙口腔崩解片及其制备方法
CN104345098B (zh) * 2013-08-05 2016-04-13 华润紫竹药业有限公司 一种测定替勃龙片剂中抗氧剂含量的方法
MX381207B (es) 2016-05-04 2025-03-12 Novalon S A Uso de alcoholes de azucar en composiciones de tibolona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
CH676470A5 (enExample) * 1988-02-03 1991-01-31 Nestle Sa
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
EP0613687B1 (en) 1993-03-05 1999-06-02 Akzo Nobel N.V. Use of a pregnane derivatives for the treatment of tumours
ES2185666T3 (es) 1993-09-03 2003-05-01 Smithkline Beecham Corp Formulacion estabilizada para comprimidos.
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100432093C (zh) * 1998-10-16 2008-11-12 欧加农股份有限公司 包含（7α,17α)-17-羟基-7-甲基-19-去甲-17-孕-5（10）-烯-20-炔-3-酮的高纯度组合物

Also Published As

Publication number Publication date
EP0975348A1 (en) 2000-02-02
US20040142028A1 (en) 2004-07-22
WO1998047517A1 (en) 1998-10-29
US6399594B2 (en) 2002-06-04
KR20010020163A (ko) 2001-03-15
NZ338028A (en) 2001-10-26
TW570798B (en) 2004-01-11
ID22763A (id) 1999-12-09
CN1146424C (zh) 2004-04-21
HUP0001780A3 (en) 2001-02-28
US20010005513A1 (en) 2001-06-28
CA2288070A1 (en) 1998-10-29
BR9809268A (pt) 2000-06-27
HUP0001780A2 (hu) 2000-12-28
ATE281836T1 (de) 2004-11-15
DE69827484T2 (de) 2005-03-17
PT975348E (pt) 2005-01-31
NO995127L (no) 1999-10-21
NO995127D0 (no) 1999-10-21
US20030119801A1 (en) 2003-06-26
RU2207133C2 (ru) 2003-06-27
US6514958B1 (en) 2003-02-04
US20040142030A1 (en) 2004-07-22
AR012480A1 (es) 2000-10-18
CN1253503A (zh) 2000-05-17
KR100580855B1 (ko) 2006-05-17
DE69827484D1 (de) 2004-12-16
AU8014698A (en) 1998-11-13
EP0975348B1 (en) 2004-11-10
PL190227B1 (pl) 2005-11-30
PL336658A1 (en) 2000-07-03
US20040142031A1 (en) 2004-07-22
TR199902530T2 (xx) 2000-05-22
IL123984A (en) 2004-09-27
CN1494908A (zh) 2004-05-12
HK1023508A1 (en) 2000-09-15
AU742037B2 (en) 2001-12-13
ZA983169B (en) 1998-10-20
ES2232949T3 (es) 2005-06-01
DK0975348T3 (da) 2005-03-07

Similar Documents

Publication Publication Date Title
JP4334616B2 (ja) 湿式粒状化による投与単位体を製造する方法
EP0377658B1 (en) A free-flowing granular composition containing ibuprofen and a method for its preparation
US5104648A (en) High ibuprofen content granulations
RU2207133C2 (ru) Стабилизированные композиции тиболона
US4911921A (en) High ibuprofen content granulations
JPS63290818A (ja) 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤
CZ282844B6 (cs) Tvrdé kapsle cytarabia-okfosfátu
JPH0474137A (ja) 徐放性製剤用基剤粉末
JPH11130663A (ja) 水難溶性成分を配合した固形剤
JP2676305B2 (ja) シタラビンオクホスファート硬カプセル剤
HK1023508B (en) Stabilized tibolone compositions
CZ374299A3 (cs) Farmaceutická léková forma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090421